Recruiting

Observational Study

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05978141

Conditions

T-cell Lymphoma

NK-Cell Lymphoma

T-cell Prolymphocytic Leukemia

T-cell Large Granular Lymphocytic Leukemia

Chronic Lymphoproliferative Disorder of NK Cells

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Optional Blood Sample and Nail Sample

Study Details

Brief summary:

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Conditions

T-cell Lymphoma

NK-Cell Lymphoma

T-cell Prolymphocytic Leukemia

T-cell Large Granular Lymphocytic Leukemia

Chronic Lymphoproliferative Disorder of NK Cells

Study ID

NCT05978141

Start date

Jul 27, 2023

Status verified date

May, 2026

Completion date

Jul 27, 2030

Anticipated

Primary completion date

Jul 27, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Written informed consent
  • Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
  • Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

  • T-cell prolymphocytic leukemia
  • T-cell large granular lymphocytic leukemia
  • Chronic lymphoproliferative disorder of NK cells
  • Aggressive NK-cell leukemia
  • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • Chronic active EBV infection of T- and NK-cell type, systemic form
  • Hydroa vacciniforme-like lymphoproliferative disorder
  • Adult T-cell leukemia/lymphoma
  • Extranodal NK/T-cell lymphoma, nasal type
  • Enteropathy-associated T-cell lymphoma
  • Monomorphic epitheliotropic intestinal T-cell lymphoma
  • Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • Sézary syndrome
  • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • Primary cutaneous Gamma-Delta T-cell lymphoma
  • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • Peripheral T-cell lymphoma, not otherwise specified
  • Angioimmunoblastic T-cell lymphoma
  • Follicular T-cell lymphoma
  • Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic large cell lymphoma, ALK-positive
  • Anaplastic large cell lymphoma, ALK-negative
  • Breast-implant associated anaplastic large cell lymphoma.
  • NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion Criteria:

  • Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with T-Cell Lymphoma

Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma

Interventions

Optional Blood Sample and Nail Sample

Participants may provide optional research blood and nail samples for biobanking and future use

Primary outcome measure

  • Number of participants populating the T-cell Lymphoma Master Repository/TCLMR [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Steven Horwitz, MD

646-608-2680horwitzs@MSKCC.ORG

Alison Moskowitz, MD

646-608-3726moskowia@mskcc.org

Locations

Memorial Sloan Kettering at Basking Ridge (All protocol activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Steven Horwitz, MD

646-608-2680

Memorial Sloan Kettering Monmouth (All protocol activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Steven Horwitz, MD

646-608-2680

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Steven Horwitz, MD

646-608-2680

Memorial Sloan Kettering Westchester (All protocol activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Steven Horwitz, MD

646-608-2680

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Steven Horwitz, MD

646-608-2680

Memorial Sloan Kettering Nassau (All protocol activities)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Steven Horwitz, MD

646-608-2680

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

May 20, 2026

Last verified

May, 2026

Keywords

  • 23-190
  • T-cell lymphoma
  • Memorial Sloan Kettering Cancer Center
  • T-cell Lymphoma Master Repository
  • TCLMR

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-05-20.